# EvidScience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evidscience

- Industry: Healthcare IT
- Headquarters: El Segundo, US
- Website: www.evidscience.com
- Latest round: Seed (Mar 1, 2019)
- Investors on record: 4

## About

EvidScience Inc. is a technology-driven company specializing in advanced artificial intelligence solutions that enhance data analysis and decision-making processes specifically within the healthcare sector.Founded in 2017 and headquartered in El Segundo, US, EvidScience Inc. focuses on leveraging artificial intelligence to improve healthcare data insights. The company was acquired by Genesis Research LLC in January 2021, which emphasized a strategic pivot towards integrating AI with human intelligence for more comprehensive data analysis. The founder's history and previous ventures are not publicly detailed.EvidES by Genesis Research specializes in advanced artificial intelligence solutions, primarily focused on enhancing data analysis and decision-making processes within the healthcare sector. Their core product, EVID AI, leverages machine learning algorithms to analyze large volumes of clinical data, providing insights that streamline research and improve patient outcomes. The platform is designed to address critical use cases such as accelerating drug discovery, optimizing clinical trial designs, and enhancing real-world evidence generation. The company serves a diverse client base, including pharmaceutical companies, biotechnology firms, and academic institutions, primarily in North America and Europe. The release of these products marks a significant advancement in the integration of AI technologies in healthcare, catering to the increasing demand for data-driven solutions in a rapidly evolving industry.EvidES generates revenue primarily through a subscription-based model, where clients pay for access to their EVID AI platform and associated services. These subscriptions may vary based on the level of service, including options for enterprise solutions that provide comprehensive access to the platform’s capabilities. Additionally, the company might engage in partnerships with pharmaceutical companies, offering tailored solutions to meet specific research needs, which could further enhance their revenue streams. The transactions typically involve annual contracts, with pricing plans structured around the volume of data processed and the specific functionalities utilized by the clients. This structured approach allows EvidES to maintain a steady revenue flow while providing essential AI-driven insights to its clients in the healthcare sector.In 2021, following the acquisition by Genesis Research LLC, EvidScience Inc. aims to innovate further by integrating AI with human intelligence for enhanced data extraction capabilities. Upcoming product enhancements and expansions into new markets are planned, although specific launch dates and targeted regions are not yet specified. The rationale for the acquisition indicates a strong focus on improving the quality and comprehensiveness of insights derived from healthcare literature, utilizing the recent funding to bolster these initiatives.

## Funding rounds

- Seed, Mar 1, 2019 — Mucker Capital, Wavemaker Three-Sixty Health
- Seed, Feb 15, 2018 — Tikehau Capital, Sprim Ventures

## Investors

- Tikehau Capital — Seed
- Sprim Ventures (https://capitalatlas.ai/funds/sprim-ventures) — Seed
- Mucker Capital (https://capitalatlas.ai/funds/mucker-capital) — Seed
- Wavemaker Three-Sixty Health (https://capitalatlas.ai/funds/wavemaker-three-sixty-health) — Seed